Align Technology (ALGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$158.64-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Align grows sales about 3% to 4% yearly. Profit margin should rise near 18%. The company buys back $200 million in stock. It invests $125 million to $150 million in new equipment.
Sales growth could slow below 3%. Profit margins might stay near 14%. Stock buybacks could stop. Capital spending may fall short.
The price is about 7% above our fair value near $176. Analysts expect 4% revenue growth. Our view aligns with these expectations.
Breaks if: stock buyback program is halted or materially reduced
Execute $200 million open market stock repurchase program approved in April 2025, funded with cash on hand and expected to complete by October 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady revenue growth and margin improvement. The current thesis is stable, supported by management's execution on key priorities.
The market seems to expect neutral performance, as ALGN is priced relatively cheap compared to peers. There is a low expectations gap, indicating that investors are not overly optimistic about future growth.
Management is on track to achieve its revenue growth target of 3% to 4% for 2026, with recent financial performance showing strength. However, there is a moderate risk due to the company's history of earnings misses in a high-miss-rate industry.
The thesis hinges on management's ability to maintain guidance and execute on priorities. Key scenarios include potential guidance cuts or sector momentum from leading healthcare companies that could influence ALGN's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: capital spending falls below $125 million in FY26
Maintain disciplined capital expenditures in fiscal 2026 within the range of $125 million to $150 million for technology upgrades and capacity expansion.
Stated as a priority in 3 of last 3 quarters. Management consistently guided capital expenditures for 2026 to be between $125 million and $150 million, reflecting disciplined investment in technology upgrades and manufacturing capacity. This guidance is stable and aligned with prior statements.
“We expect our investments in capital expenditures for fiscal 2026 to be $125 million to $150 million.”
“We expect our investments in capital expenditures for fiscal 2026 to be $125 million to $150 million.”
“We expect our investments in capital expenditures for fiscal 2026 to be $125 million to $150 million.”
Breaks if: operating margin falls below 14% in FY26
Breaks if: YoY revenue growth falls below 3% in FY26
Continue to grow worldwide revenues by 3% to 4% year-over-year in fiscal 2026, driven by Clear Aligner volume growth and international expansion.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $3.999 billion in 2024 to $4.035 billion in 2025 and reached $1.056 billion in Q2 2026, up 4.3% year-over-year. Management reaffirmed 3% to 4% revenue growth guidance for 2026, indicating delivery on this priority.
“We continue to expect 2026 worldwide revenue growth to be up 3% to 4% year-over-year.”
“For fiscal 2026 we remain confident in the outlook that we provided previously and reaffirm our full year fiscal 2026 guidance as follows: We expect 2026 worldwide revenue growth to be up 3% to 4% ye…”
“We expect 2026 worldwide revenue growth to be up 3% to 4% year-over-year.”
Overall, ALGN's fundamentals are holding up well, but the company faces risks that could impact its trajectory. Not investment advice.